DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for congenital myasthenic syndrome 9 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCongenital myasthenic syndrome 9 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for congenital myasthenic syndrome 9 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
muscle associated receptor tyrosine kinase (MUSK) — MUSK is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8S9P · 3.8 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 2024 study from Algiers reported on six patients with congenital myasthenic syndromes (CMS) carrying different mutations in different genes, with pathophysiologic profiles including slow and fast channel syndromes and low expressor of receptor. These patients were treated with innovative drugs normally indicated for non-neurological pathologies, and their outcome was toward a clear clinical improvement. The study provides Class IV evidence that for patients with CMS, some innovative treatments are effective. No specific drug names, response rates, or survival figures are given in the abstract.
A 2023 guideline for management of myasthenic syndromes exists as supplemental material but its abstract provides no data, no patient numbers, and no results. A 1999 review notes that CMS pathogenesis remained elusive until the early 1990s, when molecular genetics and in vitro neurophysiology of intercostal muscle biopsies provided insights, but it offers no treatment outcomes.
The 2024 study is small (six patients), uncontrolled, and provides only Class IV evidence. No randomised trial data, no long-term follow-up beyond the reported clinical improvement, and no information on which specific drugs were used or how they were selected for each mutation type are available. What is still missing is a properly powered trial with defined endpoints, stratification by genetic subtype, and independent replication of these findings.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology Clinical Practice · 2024 · 0 citations · open access
Innovative Therapeutic Approaches in Congenital Myasthenic Syndromes
AbstractBackground and Objectives: To provide real-word clinical follow-up data on patients carrying variations of congenital myasthenic syndromes (CMS) and who respond to some innovative drugs. Methods: Patients recruited from the Neurology Department of the Mustapha Bacha university hospital in Algiers. Treated with innovative drugs, they were monitored and their clinical progress was evaluated on the basis of clinical arguments suggestive of CMSs, but also para clinical arguments (electromyography and genetic study). Results: Six patients carrying different mutations in different genes of CMSs were studied. They had different pathophysiologic profiles (slow or fast channel syndromes, low expressor of receptor). Their therapeutic management was based on innovative drugs, normally indicated in other, non-neurological pathologies. Their outcome was toward a clear clinical improvement. Discussion: This work relates the interest of proposing treatments (outside of Pyridostigmine) in the management of CMSs. These therapies can greatly modify the prognosis of patients suffering from this orphan disease. Classification of Evidence: This study provides Class IV evidence that for patients with congenital myasthenic syndromes, some innovative treatments are effective.
Sage Journals Data · 2023 · 0 citations · open access
sj-docx-1-tan-10.1177_17562864231213240 – Supplemental material for Guideline for the management of myasthenic syndromes
AbstractSupplemental material, sj-docx-1-tan-10.1177_17562864231213240 for Guideline for the management of myasthenic syndromes by Heinz Wiendl, Angela Abicht, Andrew Chan, Adela Della Marina, Tim Hagenacker, Khosro Hekmat, Sarah Hoffmann, Hans-Stefan Hoffmann, Sebastian Jander, Christian Keller, Alexander Marx, Arthur Melms, Nico Melzer, Wolfgang Müller-Felber, Marc Pawlitzki, Jens-Carsten Rückert, Christiane Schneider-Gold, Benedikt Schoser, Bettina Schreiner, Michael Schroeter, Bettina Schubert, Jörn-Peter Sieb, Fritz Zimprich and Andreas Meisel in Therapeutic Advances in Neurological Disorders
sj-docx-1-tan-10.1177_17562864231213240 – Supplemental material for Guideline for the management of myasthenic syndromes
AbstractSupplemental material, sj-docx-1-tan-10.1177_17562864231213240 for Guideline for the management of myasthenic syndromes by Heinz Wiendl, Angela Abicht, Andrew Chan, Adela Della Marina, Tim Hagenacker, Khosro Hekmat, Sarah Hoffmann, Hans-Stefan Hoffmann, Sebastian Jander, Christian Keller, Alexander Marx, Arthur Melms, Nico Melzer, Wolfgang Müller-Felber, Marc Pawlitzki, Jens-Carsten Rückert, Christiane Schneider-Gold, Benedikt Schoser, Bettina Schreiner, Michael Schroeter, Bettina Schubert, Jörn-Peter Sieb, Fritz Zimprich and Andreas Meisel in Therapeutic Advances in Neurological Disorders
Recent Advances in Understanding Congenital Myasthenic Syndromes
AbstractCongenital myasthenic syndromes (CMS) are rare genetic disorders that continue to challenge the skills of clinical electrophysiologists, neuromuscular specialists, and general neurologists. Their pathogenesis remained elusive until the early 1990s, when advances in molecular genetics and in vitro neurophysiology of intercostal muscle biopsies provided major insights into disease mechanisms and created new ways to confirm …
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
